source
- NewLimit’s $435M megaround; Lilly’s busy dealmaking weekThe anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.BioPharma Dive · 1mo ago↗ source
- STAT+: What the pope’s encyclical on AI means for Catholic hospitals, and all of health careIn this edition of STAT's AI Prognosis: Brittany Trang analyzes the pope's encyclical on artificial intelligence for takeaways relevant for health care.STAT · 1mo ago↗ source
- STAT+: Legend Biotech emerged as a rare market winnerNew guidance for gene therapy developers, Lilly's deal for kidney drugs, and more biotech news from The ReadoutSTAT · 1mo ago